These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31012541)

  • 1. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
    Kulkarni S; Kirkiles-Smith NC; Deng YH; Formica RN; Moeckel G; Broecker V; Bow L; Tomlin R; Pober JS
    Am J Transplant; 2017 Mar; 17(3):682-691. PubMed ID: 27501352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
    Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD
    Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
    Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
    Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 37-year kidney transplantation experience at Siriraj Hospital.
    Premasathian N; Vongwiwatana A; Taweemonkongsap T; Amornvesukit T; Limsrichamrern S; Jitpraphai S; Kositamongkol P; Mahawithitwong P; Sritippayawan S; Chanchairujira T; Nualyong C; Vareesangthip K; Vasuvattakul S; Sirivatanauksorn Y
    Clin Transpl; 2010; ():141-8. PubMed ID: 21696037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials.
    Schröppel B; Akalin E; Baweja M; Bloom RD; Florman S; Goldstein M; Haydel B; Hricik DE; Kulkarni S; Levine M; Mehrotra A; Patel A; Poggio ED; Ratner L; Shapiro R; Heeger PS
    Am J Transplant; 2020 Feb; 20(2):564-572. PubMed ID: 31452319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Ruiz P; Vianna R; Burke GW
    Clin Transplant; 2018 Oct; 32(10):e13392. PubMed ID: 30152116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
    Senev A; Lerut E; Van Sandt V; Coemans M; Callemeyn J; Sprangers B; Kuypers D; Emonds MP; Naesens M
    Am J Transplant; 2019 Nov; 19(11):3100-3113. PubMed ID: 31062492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.